Hepatitis C, Chronic: all 1,090 studies
Page 8 of 11. Open to participants first (9), then studies with results posted, then the rest; newest registration first within each.
- Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)CompletedNCT01852604Phase 2
- A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV InfectionCompletedNCT01846832Phase 3
- A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis CCompletedNCT01842451Phase 2
- Interferon α 2b Pharmacovigilance StudyCompletedNCT01841775Phase 4
- Clinical Investigation of Erlotinib as an HCV Entry InhibitorStatus unknownNCT01835938Phase 1/2
- The Regression of Liver Fibrosis and Risk for Hepatocellular Carcinoma (ROLFH) StudyWithdrawnNCT01831037
- Pharmacokinetic Interactions Between Telaprevir and Un-boosted AtazanavirCompletedNCT01818856Phase 1
- A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic ImpairmentCompletedNCT01817985Phase 1
- To Evaluate the Effect of Ritonavir or Omeprazole on the Pharmacokinetics of Samatasvir (IDX719) in Healthy Participants (MK-1894-006)CompletedNCT01813552Phase 1
- Study to Evaluate Drug-Drug Interaction Between IDX719 and Simeprevir in Healthy Participants (MK-1894-004)CompletedNCT01813513Phase 1
- Prospective Cohort Study: To Provide Evidence & Guidance in Hepatitis C Virus Screening, Comparing the New Birth Cohort Recommendations From the CDC, Versus Classical Traditional Strategies With Established Risk FactorsWithdrawnNCT01813266
- An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Ribavirin Based Regimens in Patients With Chronic Hepatitis C With Previous Treatment FailureTerminatedNCT01798576
- A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis CCompletedNCT01790100Phase 2
- Comparison of Two Triple Regimens for Treatment and Retreatment of Chronic Hepatitis C InfectionCompletedNCT01771653
- Clinical Pharmacology Study of MP-424CompletedNCT01766167Phase 1
- Patterns of Early Hepatitis C Virus Decline Predict the Outcome of Interferon Therapy (sIFN-pred2)Status unknownNCT01760148
- Predictors of Response to Combined Pegylated Interferon and Ribavirin in Chronic Hepatitis C Infected Egyptian PatientsStatus unknownNCT01758939
- An Observational Study of Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) on Predictive Values of RVR on Sustained Virological Response in Different Stages of Liver Fibrosis in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1CompletedNCT01750216
- A Study of Ritonavir-Boosted Danoprevir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients of Asian Origin With Chronic Hepatitis C Genotype 1 With or Without CirrhosisCompletedNCT01749150Phase 2
- A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD)Status unknownNCT01731301Phase 4
- Miravirsen Study in Null Responder to Pegylated Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis CStatus unknownNCT01727934Phase 2
- A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis CCompletedNCT01726946Phase 2
- A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C VirusCompletedNCT01724086Phase 2
- Hepatitis C Treatment in Underserved PopulationsStatus unknownNCT01717560Not applicable
- The Role of FGL2-FcgammaRIIB Inhibitory Pathway in Human Viral HepatitisCompletedNCT01711164
- Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal DysfunctionCompletedNCT01708889Phase 1
- SIMpill Medication Dispensing Device in the Treatment of HCVWithdrawnNCT01691235
- Randomized Controlled Open Label Trial of Peg Alpha 2a Interferon and Adjusted-dose of Ribavirin vs. Standard Therapy in the Treatment of Naive Chronic Hepatitis C Patients Infected With Genotype 4CompletedNCT01686789Phase 4
- Study to Evaluate the Treatment for Chronic Hepatitis C With Normal Transaminases in HIV Positive PatientsCompletedNCT01684787Phase 4
- An Observational Study of Pegasys in Dual- or Triple-Therapy in Patients With Chronic Hepatitis CCompletedNCT01679834
- An Observational Study To Assess Liver Fibrosis Stages in Patients With Chronic Hepatitis C InfectionCompletedNCT01671046
- Effects of Metformin, Pegylated Interferon Alpha and Ribavirin for Chronic Hepatitis C With Insulin ResistanceStatus unknownNCT01664845Phase 2/3
- Vitamin D as an add-on Therapy With Pegylated Interferon and Ribavirin for Chronic Hepatitis cStatus unknownNCT01655966Phase 3
- Boceprevir With Peginterferon Alfa-2b and Ribavirin in the Treatment-naive Patients Infected With Genotype 4 Chronic Hepatitis C InfectionStatus unknownNCT01653236Phase 3
- Study in HCV-Infected Patients to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of JNJ-47910382TerminatedNCT01651767Phase 1
- Hansenula-derived Pegylated Interferon in Treatment of Patients With Chronic Hepatitis CStatus unknownNCT01649245Phase 4
- Drug Interaction Study to Assess the Effect of Co-Administered Miravirsen and Telaprevir in Healthy SubjectsCompletedNCT01646489Phase 1
- Safety and Tolerability of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for the Treatment of Vietnamese Subjects With Chronic Hepatitis C Genotype 1 (P08599)WithdrawnNCT01641666Phase 3
- Effect of Teleprevir in Triple Therapy on Intrahepatic Immunological MechanismsCompletedNCT01641094
- Sustained Virological Response (SVR)Rate of Pegasys Plus Ribavirin in Patients With Chronic Hepatitis CTerminatedNCT01639547Not applicable
- Histologic Changes and Noninvasive Assessment in Hepatitis C Patients Treated with Peginterferon Alpha-2a and RibavirinCompletedNCT01634919
- Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis CWithdrawnNCT01629732Phase 2
- ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based TreatmentCompletedNCT01628094Phase 2
- BIP48 (Peginterferon Alfa 2b 48kDa) Compared With Pegasys® (Peginterferon 2a 40kDa) for Treatment of Chronic Hepatitis CStatus unknownNCT01623336Phase 2/3
- An Observational Study of Peginterferon Alfa-2a in Combination With Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver CirrhosisCompletedNCT01609049
- A Phase III Study of BI201335 in Treatment-naive and Prior Relapser Patients With Chronic Hepatitis C InfectionWithdrawnNCT01608737Phase 3
- Pharmacogenomics Study on IL28B Genetic Variants in Chinese Children With Hepatitis C Virus InfectionStatus unknownNCT01607021
- Efficacy and Effectiveness of PegInterferon and Ribavirin in Korean Patients With Chronic Hepatitis CCompletedNCT01596517Phase 4
- A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis CCompletedNCT01591668Phase 1
- First in Human Study of ALS-002200; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1CompletedNCT01590407Phase 1
- Efficacy and Safety of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P08034)WithdrawnNCT01590225Phase 3
- Dose Finding Study of Pegylated-P-Interferon-alpha-2b(P1101) in Treatment-Naive Subjects With Hepatitis C Virus Genotype 1 InfectionCompletedNCT01587586Phase 2
- A Study of the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-47910382 at Different Doses and Dose Regimens in Asian Genotype-1, Chronic, HCV-Infected PatientsTerminatedNCT01586325Phase 1
- Efficacy and Safety Study of Peginterferon Alfa-2b in Chinese Chronic Hepatitis C PatientsCompletedNCT01581398Phase 3
- VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis CCompletedNCT01581138Phase 2
- A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C Genotype 1 Who Have Failed Prior HCV Protease Inhibitor TreatmentWithdrawnNCT01579019Phase 2
- Predictive Factors of the Treatment Failure in Hepatitis C Virus (HCV) Infected Patients Treated With TelaprevirCompletedNCT01577069
- Effects of Activity and Education Program on Patients With Chronic Hepatitis C InfectionStatus unknownNCT01572233Not applicable
- An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver TransplantationCompletedNCT01571583Phase 3
- A Study to Evaluate the Efficacy, Safety and Tolerability of TMC435 in Combination With PegIFN Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naïve or Treatment-Experienced, Chronic Hepatitis C Virus Genotype-4 Infected PatientsCompletedNCT01567735Phase 3
- A Pilot Study Evaluating Safety of Sitagliptin Combined With Peg-IFN Alfa-2a + Ribavirin in Chronic Hepatitis C PatientsTerminatedNCT01567540Phase 1
- A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-8325 in Hepatitis C-Infected Males (MK-8325-002)TerminatedNCT01554189Phase 1
- First in Human Study of ALS-002158; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1TerminatedNCT01554085Phase 1
- Evaluation of Hepatic Pharmacokinetics for Grazoprevir (MK-5172) in Participants With Chronic Hepatitis C (MK-5172-022)WithdrawnNCT01547312Phase 1
- Observational Study of B-Cell Non Hodgkin Lymphomas (NHL) Associated With Hepatitis C Virus (HCV)Status unknownNCT01545544
- Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical TrialCompletedNCT01525810
- Multiple Ascending Dose Study of BMS-929075 in Hepatitis C Virus (HCV) Infected PatientsWithdrawnNCT01525212Phase 1
- A Study to Evaluate the Safety, Tolerability, and PK in Healthy Volunteers and HCV Genotype 1 Infected PatientsCompletedNCT01523990Phase 1
- 24 VS 48-WEEK TREATMENT WITH PEG-IFN ALPHA-2A IN PATIENTS WITH GENOTYPE 2/3 CHRONIC HEPATITIS CWithdrawnNCT01517308Phase 3
- A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated CirrhosisCompletedNCT01516918Phase 2
- French Cohort of Therapeutic Failure and Resistances in Patients Treated With a Protease Inhibitor (Telaprevir or Boceprevir), Pegylated Interferon and RibavirinCompletedNCT01514890
- An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)CompletedNCT01513941Phase 3
- A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy SubjectsCompletedNCT01511432Phase 1
- Keyhole Limpet Hemocyanin in Chronic Hepatitis CCompletedNCT01509391Not applicable
- Early Access Program of Telaprevir With Peginterferon and Ribavirin in Chronic Hepatitis C SubjectsNo longer availableNCT01508286
- Study of Hepatitis C Virus (HCV) Nonstructural Protein 5a (NS5A) Inhibitor IDX719 in Healthy and HCV-Infected Participants (MK-1894-001)CompletedNCT01508156Phase 1/2
- Telaprevir Open-Label Study in Co-Infected PatientsCompletedNCT01500616Phase 3
- Role of FXR in Hepatitis C Virus ReplicationTerminatedNCT01492998Not applicable
- Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical TrialCompletedNCT01492504
- A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated CirrhosisCompletedNCT01483742Phase 2
- A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis CCompletedNCT01482403Phase 2
- A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis CCompletedNCT01482390Phase 2
- The Predictive Value of On-treatment Virological Response for Sustained Virological Response in Chronic Hepatitis CCompletedNCT01464008
- To Study the Efficacy and Safety of Renessans in Chronic HCV PatientsStatus unknownNCT01463592Phase 3
- Oral Administration of Anti-CD3 Monoclonal Antibody in Non-responder Genotype-I Chronic Hepatitis C SubjectsStatus unknownNCT01459419Phase 2
- Boceprevir/PegIFN α-2b/Riba in HCV+ Gt1 Menopausal Women, Nonresponders to PegIFN/Riba or Treatment-naives (MEN_BOC)Status unknownNCT01457937Phase 3
- A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic ResponseCompletedNCT01457768
- Gilead Sustained Virologic Response (SVR) RegistryCompletedNCT01457755
- Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available MedicationsCompletedNCT01455090Phase 2
- Pharmacogenomic Research in Korean Patients With Hepatitis CCompletedNCT01453244
- A Phase 1 Study of PPI-668 in Healthy Volunteers and Patients With Hepatitis C Virus (HCV) Genotype 1CompletedNCT01448200Phase 1
- A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for Patients With Genotype 1 Hepatitis C and IL28B CC PolymorphismStatus unknownNCT01441804Phase 3
- Add Vitamin D With Standard of Care for Chronic Hepatitis C PatientsCompletedNCT01439776Phase 4
- Q-Trial in Patients With Hepatitis CCompletedNCT01438320Phase 1
- GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) InfectionCompletedNCT01435226Phase 2
- Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C InfectionCompletedNCT01435044Phase 2
- Response to Pegylated Interferon and Ribavirin in Chinese Patients With Chronic Hepatitis C Genotypes 1 Versus 2/3 Versus 6CompletedNCT01433887Phase 3
- Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-9669 in Subjects With Chronic Hepatitis C Virus InfectionCompletedNCT01431898Phase 1
- Effect of Boceprevir on HCV-specific T Cell ResponsesCompletedNCT01403181
- Menopause is a Critical Factor in Determining Failure of Antiviral Therapy in Women With Chronic Hepatitis CCompletedNCT01402583